Scorpius Holdings, Inc.

SCPX

US42237K4094

Pharmaceuticals

Market Closed - Nyse Other stock markets 21:00:00 23/05/2024 BST			5-day change	1st Jan Change
0.1042 ^USD	-9.39%		+4.10%	-76.33%

05-14	Top Midday Decliners	MT
05-01	Scorpius Holdings, Inc. announced that it expects to receive $0.75 million in funding	CI

Jeff T. Hutchins Leave as A Chief Scientific and Operating Officer from Heat Biologics, Inc

November 02, 2020 at 12:32 pm

On November 1, 2020, it was determined and announced to the Heat Biologics, Inc.'s internal staff that Jeff T. Hutchins, Ph.D., the Company's Chief Scientific and Operating Officer, will be leaving the Company on December 31, 2020, upon the expiration of the 4-year term of his current employment agreement.

Latest news about Scorpius Holdings, Inc.

Top Midday Decliners	05-14	MT
Scorpius Holdings, Inc. announced that it expects to receive $0.75 million in funding	04-30	CI
Scorpius Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	04-26	CI
Scorpius Holdings Gets Non-Compliance Notice From NYSE American	04-23	MT
North American Morning Briefing : Stock Futures -2-	04-11	DJ
North American Morning Briefing : Focus Turns to -2-	04-04	DJ
US Stock Futures Flat Ahead of Powell Speech After Reaching Record Highs on Thursday	03-22	MT
Scorpius Holdings, Inc. Wins Contract in Excess of $1 Million with NIH-Funded Researcher at a Major University	03-19	CI
Scorpius Closes $1.5 Million Public Offering	03-13	MT
Scorpius Holdings Prices Stock Offering at $0.15 a Share	03-08	MT
Scorpius Holdings, Inc. Provides Earnings Guidance for the Fourth Quarter of 2023	03-07	CI
NightHawk Biosciences, Inc. will Change its Name to Scorpius Holdings, Inc	02-06	CI
Nighthawk Biosciences, Inc. Announces the Promotion of Joe Payne to President and Chief Operating Officer of Its Scorpius Biomanufacturing Subsidiary	02-01	CI
NightHawk?s Scorpius BioManufacturing Subsidiary Receives Multimillion- Dollar Contract with a Publicly Traded Biotech Company to Support its Phase 2 Clinical Program	01-25	CI
NightHawk Biosciences Postpones Planned Name Change	01-22	MT
Nighthawk?S Scorpius Biomanufacturing Subsidiary Commences Work on Preclinical Program for New Client	01-16	CI
NightHawk Biosciences, Inc. Announces Executive Appointments	01-08	CI
NightHawk Biosciences, Inc. has Changed its Ticker to SCPX from NHWK	01-08	CI
Scorpius BioManufacturing Commences Work on Multi-Million-Dollar Development and Manufacturing Agreement for A Leading National University	01-03	CI
Jeffrey Wolf acquired Elusys Therapeutics, Inc. from NightHawk Biosciences, Inc..	12-26	CI
NightHawk Biosciences, Inc. announced that it expects to receive $2.25 million in funding	12-10	CI
NightHawk Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-20	CI
Jeffrey Wolf submitted a preliminary, non-binding offer letter to acquire Elusys Therapeutics, Inc. from NightHawk Biosciences, Inc. for $40.5 million.	20/08/23	CI
NightHawk Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/08/23	CI
NightHawk Biosciences, Inc.(NYSEAM:NHWK) dropped from Russell Microcap Value Index	23/06/23	CI

Chart Scorpius Holdings, Inc.

Duration

Period

More charts

Company Profile

Scorpius Holdings, Inc., formerly NightHawk Biosciences, Inc., is an integrated contract development and manufacturing company. The Company is focused on advancing biologic and cell therapy programs to the clinic and beyond. It offers a broad array of analytical testing, process development, and manufacturing services to pharmaceutical and biotech companies at its facilities in San Antonio, Texas. Its analytical services include development of a comprehensive range of analytical test methods to characterize complex biologics, including cell therapy-based products, protein therapeutics, vaccines and advanced therapies. Its Clinical Biomanufacturing includes cGMP Mammalian Cell Culture, and cGMP Microbial Fermentation. Its San Antonio facility is focused on the commercial-scale manufacturing of biodefense-focused molecules and biologics therapeutics. Its biomanufacturing services focus on accelerating product development timelines from pre-clinical evaluation to first-in-human studies.

Sector

Pharmaceuticals

Calendar

06/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

0.1042

Average target price

Consensus

Quarterly earnings - Rate of surprise

Company calendar

Sector Specialty & Advanced Pharmaceuticals

	1st Jan change	Capi.
SCORPIUS HOLDINGS, INC.	-76.33%	10.03M
KYOWA KIRIN CO. LTD.	+8.35%	8.79B
SK BIOPHARMACEUTICALS CO., LTD.	-15.14%	4.88B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+50.73%	4.73B
YUHAN CORPORATION	+4.36%	3.92B
BETTA PHARMACEUTICALS CO., LTD.	-26.13%	2.2B
INDIVIOR PLC	+12.48%	2.28B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+16.45%	2.11B
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-33.59%	2.08B
VELOXIS PHARMACEUTICALS A/S	-0.50%	1.64B

Specialty & Advanced Pharmaceuticals

Scorpius Holdings, Inc.

Equities

SCPX

US42237K4094

Pharmaceuticals

Jeff T. Hutchins Leave as A Chief Scientific and Operating Officer from Heat Biologics, Inc

Latest news about Scorpius Holdings, Inc.

Chart Scorpius Holdings, Inc.

Company Profile

Income Statement Evolution

Analysts' Consensus

Quarterly earnings - Rate of surprise

Sector Specialty & Advanced Pharmaceuticals